A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy

被引：0
作者：
M Tanioka
A Kitao
K Matsumoto
N Shibata
S Yamaguchi
K Fujiwara
H Minami
N Katakami
S Morita
S Negoro
机构：
[1] Medical Oncology,Department of Pharmacy
[2] Hyogo Cancer Center,Division of Pulmonary Medicine
[3] Medical Oncology/Hematology,undefined
[4] Kobe University Graduate School of Medicine,undefined
[5] Hyogo Cancer Center,undefined
[6] Gynecologic Oncology,undefined
[7] Hyogo Cancer Center,undefined
[8] Kobe City Medical Center General Hospital,undefined
来源：
British Journal of Cancer | 2013年 / 109卷
关键词：
aprepitant; moderately emetogenic chemotherapy; carboplatin; female; alcohol use;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：859 / 865
页数：6
相关论文
共 50 条
  • [41] A chinese medicine formula (kunbixiao granule) for female rheumatoid arthritis: Study protocol for a double-blind, randomized, placebo-controlled trial
    Wan, Yingying
    Yang, Jiaxi
    Ma, Tianyue
    Wang, Wenqian
    Wang, Haonan
    Sun, Wenting
    Ye, Wanting
    Yang, Lin
    Ren, Jianxun
    Kou, Qiuai
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [42] Efficacy and safety of alprostadil cream for the treatment of female sexual arousal disorder: A double-blind, placebo-controlled study in Chinese population
    Liao, Qinping
    Zhang, Miao
    Geng, Li
    Wang, Xiangping
    Song, Xuehong
    Xia, Pei
    Lu, Tao
    Lu, Mingqi
    Liu, Vivian
    JOURNAL OF SEXUAL MEDICINE, 2008, 5 (08) : 1923 - 1931
  • [43] A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder
    Brown, E. Sherwood
    McArdle, Meagan
    Palka, Jayme
    Bice, Collette
    Ivleva, Elena
    Nakamura, Alyson
    McNutt, Markey
    Patel, Zena
    Holmes, Traci
    Tipton, Shane
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 43 : 92 - 101
  • [44] Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
    Ledermann, Jonathan A.
    Embleton, Andrew C.
    Raja, Fharat
    Perren, Timothy J.
    Jayson, Gordon C.
    Rustin, Gordon J. S.
    Kaye, Stan B.
    Hirte, Hal
    Eisenhauer, Elizabeth
    Vaughan, Michelle
    Friedlander, Michael
    Gonzalez-Martin, Antonio
    Stark, Daniel
    Clark, Elizabeth
    Farrelly, Laura
    Swart, Ann Marie
    Cook, Adrian
    Kaplan, Richard S.
    Parmar, Mahesh K. B.
    LANCET, 2016, 387 (10023) : 1066 - 1074
  • [45] Efficacy of Raloxifene as Add-on Therapy on Disease Activity of Postmenopausal Women with Rheumatoid Arthritis: A Double-blind, Randomized, Placebo-controlled Clinical Trial
    Sahebari, Maryam
    Yazdi, Maryam Sarafraz
    Aghili, Seyedeh Mehrnaz
    Esmaily, Habibollah
    Saeidi, Sara
    Salari, Masoumeh
    CURRENT RHEUMATOLOGY REVIEWS, 2023, 19 (01) : 93 - 101
  • [46] Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Hashimoto, Hironobu
    Abe, Masakazu
    Tokuyama, Osamu
    Mizutani, Hideaki
    Uchitomi, Yosuke
    Yamaguchi, Takuhiro
    Hoshina, Yukari
    Sakata, Yasuhiko
    Takahashi, Takako Yanai
    Nakashima, Kazuhisa
    Nakao, Masahiko
    Takei, Daisuke
    Zenda, Sadamoto
    Mizukami, Koki
    Iwasa, Satoru
    Sakurai, Michiru
    Yamamoto, Noboru
    Ohe, Yuichiro
    LANCET ONCOLOGY, 2020, 21 (02) : 242 - 249
  • [47] A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
    Ciuleanu, T.
    Bazin, I.
    Lungulescu, D.
    Miron, L.
    Bondarenko, I.
    Deptala, A.
    Rodriguez-Torres, M.
    Giantonio, B.
    Fox, N. L.
    Wissel, P.
    Egger, J.
    Ding, M.
    Kalyani, R. N.
    Humphreys, R.
    Gribbin, M.
    Sun, W.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 680 - 687
  • [48] A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)
    Gaafar, Rabab M.
    Surmont, Veerle F.
    Scagliotti, Giorgio V.
    Van Klaveren, Rob J.
    Papamichael, Demetris
    Welch, John J.
    Hasan, Baktiar
    Torri, Valter
    van Meerbeeck, Jan P.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (15) : 2331 - 2340
  • [49] Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy - A phase 3 randomized, double-blind, placebo-controlled, crossover trial (NOOC3)
    Rao, Ravi D.
    Michalak, John C.
    Sloan, Jeff A.
    Loprinzi, Charles L.
    Soori, Gamini S.
    Nikcevich, Daniel A.
    Warner, David O.
    Novotny, Paul
    Kutteh, Leila A.
    Wong, Gilbert Y.
    CANCER, 2007, 110 (09) : 2110 - 2118
  • [50] Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy - A phase 3 randomized, double-blind, placebo-controlled trial, N01C3
    Rao, Ravi D.
    Flynn, Patrick J.
    Sloan, Jeff A.
    Wong, Gilbert Y.
    Novotny, Paul
    Johnson, David B.
    Gross, Howard M.
    Renno, Samer I.
    Nashawaty, Mohammed
    Loprinzi, Charles L.
    CANCER, 2008, 112 (12) : 2802 - 2808
12345